Current opinion in hematology
-
Curr. Opin. Hematol. · Jul 1994
ReviewRecent advances in biological and therapeutic aspects of myeloproliferative disorders.
Chronic myeloproliferative disorders are clonal neoplasias that originate from a clonal pluripotent stem cell and may have a more or less pronounced tendency to acute progression. Except for chronic myelogenous leukemia marked by the Ph chromosome, the BCR/ABL rearrangement, or both, the other chronic myeloproliferative disorder subtypes show less specific, although recurrent, karyotypic and molecular abnormalities. We report here more recent advances in cytogenetics, molecular biology, and treatment of the most common chronic myeloproliferative disorders.
-
Curr. Opin. Hematol. · May 1994
ReviewHematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321.
The clinical uses of granulocyte-macrophage colony-stimulating factor (GM-CSF) are expanding. GM-CSF was originally approved for use after autologous bone marrow transplantation. More recent phase III studies using GM-CSF after allogenic marrow transplantation show a similar reduction in the duration of neutropenia and monocytopenia. ⋯ PIXY321 is a fusion protein of GM-CSF and interleukin-3. PIXY321 was developed, in part, because in vitro and in vivo laboratory studies suggested synergy between its two components. Phase I-II clinical studies using PIXY321 are preliminary but show encouraging results with stimulation of multilineage hematopoiesis.